Sandra Lapinska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra Lapinska has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Bogdan Pasaniuc
Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
4 shared publications - Kangcheng Hou
Department of Biomedical Informatics, Harvard Medical School, Boston, MA
2 shared publications - Ravi Mandla
Graduate Program in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, USA
2 shared publications Xinzhe Li
University of Pennsylvania
2 shared publications- Zhuozheng Shi
Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2 shared publications Aditya Pimplaskar
1 shared publication
Latest Publications
- Open Access
Implementation of the genome-informed risk assessment (GIRA) may lead to large disruptions to the health system
The Genome Informed Risk Assessment (GIRA) report from eMERGE has become a standard approach to implement genomic precision medicine at scale. Here, we assess GIRA's utility and impact in a health care system independent of eMERGE, focusing on 9 adult conditions using the Penn Medicine Biobank (PMBB, n=48,279). We find a large number of patients - 50.1% (n=24,185) - were deemed by GIRA as high-risk for at least one of the 9 conditions with 30.4% (n=14,676) due to polygenic and/or monogenic risk. Stratifying by ancestry revealed significant differences in high-risk proportions, with higher rates in African/African American (AFR) (56.6% vs. 50.1%, p=7.43x10-36) and lower rates in East (42.0%) and South Asian (40.0%). Increased high-risk rates were observed in the lowest quartile of social deprivation index, highlighting the influence of environmental factors and access to care on GIRA's utility. GIRA was a good predictor of prevalent cases (in-line with the eMERGE GIRA reported results); incident case prediction was substantially attenuated for 5 of the 9 conditions (e.g., OR of 2.36 vs. HR of 1.31 for atrial fibrillation (AFIB)). We find demographic compositions of high-risk patients differed from the incident cases for some of the conditions; for example, high-risk for AFIB individuals where enriched for European ancestries in contrast with incident AFIB cases that were enriched for AFR ancestries. Overall, our results show the accuracy of GIRA as a biomarker to stratify high-risk patients for precision medicine and highlight implementation challenges in its impact on the health system if implemented at scale.
Open AccessImplementation of the genome-informed risk assessment (GIRA) may lead to large disruptions to the health system
The Genome Informed Risk Assessment (GIRA) report from eMERGE has become a standard approach to implement genomic precision medicine at scale. Here, we assess GIRA's utility and impact in a health care system independent of eMERGE, focusing on 9 adult conditions using the Penn Medicine Biobank (PMBB, n=48,279). We find a large number of patients - 50.1% (n=24,185) - were deemed by GIRA as high-risk for at least one of the 9 conditions with 30.4% (n=14,676) due to polygenic and/or monogenic risk. Stratifying by ancestry revealed significant differences in high-risk proportions, with higher rates in African/African American (AFR) (56.6% vs. 50.1%, p=7.43x10-36) and lower rates in East (42.0%) and South Asian (40.0%). Increased high-risk rates were observed in the lowest quartile of social deprivation index, highlighting the influence of environmental factors and access to care on GIRA's utility. GIRA was a good predictor of prevalent cases (in-line with the eMERGE GIRA reported results); incident case prediction was substantially attenuated for 5 of the 9 conditions (e.g., OR of 2.36 vs. HR of 1.31 for atrial fibrillation (AFIB)). We find demographic compositions of high-risk patients differed from the incident cases for some of the conditions; for example, high-risk for AFIB individuals where enriched for European ancestries in contrast with incident AFIB cases that were enriched for AFR ancestries. Overall, our results show the accuracy of GIRA as a biomarker to stratify high-risk patients for precision medicine and highlight implementation challenges in its impact on the health system if implemented at scale.
- Open Access
Genome-wide analysis implicates inner ear development in Ménière’s disease
Ménière’s disease (MD) is a chronic inner ear disorder characterized by recurrent vertigo, fluctuating sensorineural hearing loss, and tinnitus. Despite these distinctive symptoms, its etiology remains poorly understood. We performed a genome-wide meta-analysis of 8,969 cases and 1,962,542 controls across five large biobanks, identifying five independent genome-wide significant loci and estimating an observed-scale SNP heritability of 7% (SE 0.8%), consistent with a modest but significant genetic contribution to MD risk. Fine-mapping and integrative functional analyses implicate two convergent biological processes – developmental regulation of the inner ear, involving EYA4, EYA1 , and LMO4 – and retinoic acid metabolism, with loci near CYP26A1/C1 and ALDH1A2 suggesting disrupted RA signaling in sensory and fluid-pressure homeostasis. These developmental regulator genes are robustly expressed in fetal and adult human inner ear cell types, supporting a model in which altered developmental programs predispose to adult vestibular and auditory dysfunction. Phenome-wide and genetic correlation analyses further reveal shared genetic architecture between MD and related traits, including vertigo, tinnitus, hearing loss, migraine, and sleep apnea, situating MD within a broader spectrum of sensory and neurological disorders. Collectively, these findings establish a genetic framework for Ménière’s disease risk and implicate developmental regulators and retinoic acid signaling as key contributing pathways.
Open AccessGenome-wide analysis implicates inner ear development in Ménière’s disease
Ménière’s disease (MD) is a chronic inner ear disorder characterized by recurrent vertigo, fluctuating sensorineural hearing loss, and tinnitus. Despite these distinctive symptoms, its etiology remains poorly understood. We performed a genome-wide meta-analysis of 8,969 cases and 1,962,542 controls across five large biobanks, identifying five independent genome-wide significant loci and estimating an observed-scale SNP heritability of 7% (SE 0.8%), consistent with a modest but significant genetic contribution to MD risk. Fine-mapping and integrative functional analyses implicate two convergent biological processes – developmental regulation of the inner ear, involving EYA4, EYA1 , and LMO4 – and retinoic acid metabolism, with loci near CYP26A1/C1 and ALDH1A2 suggesting disrupted RA signaling in sensory and fluid-pressure homeostasis. These developmental regulator genes are robustly expressed in fetal and adult human inner ear cell types, supporting a model in which altered developmental programs predispose to adult vestibular and auditory dysfunction. Phenome-wide and genetic correlation analyses further reveal shared genetic architecture between MD and related traits, including vertigo, tinnitus, hearing loss, migraine, and sleep apnea, situating MD within a broader spectrum of sensory and neurological disorders. Collectively, these findings establish a genetic framework for Ménière’s disease risk and implicate developmental regulators and retinoic acid signaling as key contributing pathways.
- 27 June 2025
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 112 (8) , 1877-1891
Exploring depression treatment response by using polygenic risk scoring across diverse populations
- 27 June 2025
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 112 (8) , 1877-1891
Exploring depression treatment response by using polygenic risk scoring across diverse populations
- Open Access
Quantitative trait loci mapping of gene expression and chromatin accessibility in primary fibroblast reveals shared allelic effects between Latin American and European ancestries
Quantitative Trait Locus (QTL) analysis of molecular data has identified genetic variants associated with traits such as gene expression, and colocalization of these functional QTL with GWAS risk loci has offered insights into the genetic basis of human disease. We employed gene expression (RNA-seq) and chromatin accessibility (ATAC-seq) obtained from human primary fibroblasts to investigate quantitative trait loci (QTLs) in cohorts ascertained for bipolar disorder of European (n=150) and Latin American (n=96) ancestries. Leveraging data from three countries of origin (The Netherlands, Colombia, Costa Rica) within our cohort, we characterized differences among individuals at the SNP, gene, and accessible-chromatin levels to compute ancestry-specific expression (e)QTLs and chromatin-accessibility (ca)QTLs. Across ancestries, we observed R² ≥ 0.93 for eQTL effect sizes and R² ≥ 0.95 for caQTLs, indicating a high degree of concordance. Integrating chromatin data with expression and genotype information enabled precise fine-mapping of eQTLs, yielding 203 high-confidence (posterior probability > 90 %) regulatory pathways. In downstream analyses, transcriptome-wide (TWAS) and chromatin-wide (CWAS) association studies with brain- and skin-related GWAS identified 36 TWAS-significant genes and 77 CWAS-significant open chromatin regions. These findings underscore the shared genetic regulatory mechanisms across European and Latin American ancestries, while demonstrating that ancestry-specific reference panels enhance the accuracy of TWAS and CWAS in diverse populations.
Open AccessQuantitative trait loci mapping of gene expression and chromatin accessibility in primary fibroblast reveals shared allelic effects between Latin American and European ancestries
Quantitative Trait Locus (QTL) analysis of molecular data has identified genetic variants associated with traits such as gene expression, and colocalization of these functional QTL with GWAS risk loci has offered insights into the genetic basis of human disease. We employed gene expression (RNA-seq) and chromatin accessibility (ATAC-seq) obtained from human primary fibroblasts to investigate quantitative trait loci (QTLs) in cohorts ascertained for bipolar disorder of European (n=150) and Latin American (n=96) ancestries. Leveraging data from three countries of origin (The Netherlands, Colombia, Costa Rica) within our cohort, we characterized differences among individuals at the SNP, gene, and accessible-chromatin levels to compute ancestry-specific expression (e)QTLs and chromatin-accessibility (ca)QTLs. Across ancestries, we observed R² ≥ 0.93 for eQTL effect sizes and R² ≥ 0.95 for caQTLs, indicating a high degree of concordance. Integrating chromatin data with expression and genotype information enabled precise fine-mapping of eQTLs, yielding 203 high-confidence (posterior probability > 90 %) regulatory pathways. In downstream analyses, transcriptome-wide (TWAS) and chromatin-wide (CWAS) association studies with brain- and skin-related GWAS identified 36 TWAS-significant genes and 77 CWAS-significant open chromatin regions. These findings underscore the shared genetic regulatory mechanisms across European and Latin American ancestries, while demonstrating that ancestry-specific reference panels enhance the accuracy of TWAS and CWAS in diverse populations.
- 20 December 2021
- Published by Springer Nature in Nature Genetics
- Vol. 54 (1) , 30-39
Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification
Although the cohort-level accuracy of polygenic risk scores (PRSs)—estimates of genetic value at the individual level—has been widely assessed, uncertainty in PRSs remains underexplored. In the present study, we show that Bayesian PRS methods can estimate the variance of an individual’s PRS and can yield well-calibrated credible intervals via posterior sampling. For 13 real traits in the UK Biobank (n = 291,273 unrelated ‘white British’), we observe large variances in individual PRS estimates which impact interpretation of PRS-based stratification; averaging across traits, only 0.8% (s.d. = 1.6%) of individuals with PRS point estimates in the top decile have corresponding 95% credible intervals fully contained in the top decile. We provide an analytical estimator for the expectation of individual PRS variance as a function of SNP heritability, number of causal SNPs and sample size. Our results showcase the importance of incorporating uncertainty in individual PRS estimates into subsequent analyses.
- 20 December 2021
- Published by Springer Nature in Nature Genetics
- Vol. 54 (1) , 30-39
Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification
Although the cohort-level accuracy of polygenic risk scores (PRSs)—estimates of genetic value at the individual level—has been widely assessed, uncertainty in PRSs remains underexplored. In the present study, we show that Bayesian PRS methods can estimate the variance of an individual’s PRS and can yield well-calibrated credible intervals via posterior sampling. For 13 real traits in the UK Biobank (n = 291,273 unrelated ‘white British’), we observe large variances in individual PRS estimates which impact interpretation of PRS-based stratification; averaging across traits, only 0.8% (s.d. = 1.6%) of individuals with PRS point estimates in the top decile have corresponding 95% credible intervals fully contained in the top decile. We provide an analytical estimator for the expectation of individual PRS variance as a function of SNP heritability, number of causal SNPs and sample size. Our results showcase the importance of incorporating uncertainty in individual PRS estimates into subsequent analyses.